Neurologists frequently encounter patients with psychiatric conditions, either primary or as a complication of neurologic disease. All neurologists see patients with mood disorders, and many are comfortable prescribing a first-line agent such as an SSRI. In fact, a majority of mood disorders are treated by non-psychiatrists. Newer data shows the high prevalence of mood disorders in neurologic disease, such as Parkinson disease, stroke, and dementia. Depression occurs in a third of survivors of stroke and is associated with higher mortality. Depression has also been noted to increase the likelihood of later dementia.
Dementia Elderly and dementia Pharmacology for the elderly Neurology and the elderly Psychopharmacology for neurologists Psychiatric disorders and the neurologist
This is a preview of subscription content, log in to check access.
Cohen-Mansfield J, Wirtz PW. The reasons for nursing home entry in an adult day care population: caregiver reports versus regression results. J Geriatr Psychiatry Neurol. 2009;22(4):274–81.CrossRefPubMedGoogle Scholar
de Vugt ME, Stevens F, Aalten P, et al. A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. Int Psychogeriatr. 2005;17:577–89.CrossRefPubMedGoogle Scholar
Ballard C, Creese B, Aarsland D. Atypical antipsychotics for the treatment of behavioural and psychological symptoms of dementia with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf. 2011;10:35–43.CrossRefPubMedGoogle Scholar
Trends in elderly patients’ office visits for the treatment of depression according to physician specialty: 1985–1999. J Behav Health Serv Res. 2003;30(3):332–41.Google Scholar
Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke J Cereb Circ. 2005;36:1330–40.CrossRefGoogle Scholar
Verdelho A, et al. Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes. J Neurol Neurosurg Psychiatry. 2013;84(11):1250–4.CrossRefPubMedGoogle Scholar
Yaffe K, Hoang TD, Byers AL, Barnes DE, Friedl KE. Lifestyle and health-related risk factors and risk of cognitive aging among older veterans. Alzheimers Dement. 2014;10:S111–21.CrossRefGoogle Scholar
Molden E, Garcia BH, Braathen P, Eggen AE. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol. 2005;61(2):119–25.CrossRefPubMedGoogle Scholar
Preskorn, Shah R, Neff M, Golbeck AL, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract. 2007;13(1):5–12.CrossRefPubMedGoogle Scholar
Mate KE, Kerr KP, Pond D, et al. Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. Drugs Aging. 2015;32:159-67.CrossRefGoogle Scholar